Compare · AIH vs ILMN
AIH vs ILMN
Side-by-side comparison of Aesthetic Medical International Holdings Group Ltd. (AIH) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIH and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.66B, about 239.6x AIH ($102.9M).
- ILMN has hit the wire 21 times in the past 4 weeks while AIH has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for AIH).
- Company
- Aesthetic Medical International Holdings Group Ltd.
- Illumina Inc.
- Price
- $0.40-16.18%
- $162.84-0.08%
- Market cap
- $102.9M
- $24.66B
- 1M return
- -
- +28.56%
- 1Y return
- -
- +100.79%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2000
- News (4w)
- 0
- 21
- Recent ratings
- 0
- 25
Aesthetic Medical International Holdings Group Ltd.
Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 28 treatment centers in China, Hong Kong, and Singapore. The company was founded in 1997 and is headquartered in Shenzhen, China.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest AIH
- Aesthetic Medical International Holdings Group Ltd. Announces the Commencement of OTCQX Trading
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- SEC Form 6-K filed by Aesthetic Medical International Holdings Group Ltd.
- Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Delisting Decision from the Nasdaq Hearings Panel
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Aesthetic Medical International Holdings Group Announces Receipt Of Decision From Nasdaq Hearings Panel For Conditional Continued Listing
- SEC Form 6-K filed by Aesthetic Medical International Holdings Group Ltd.
Latest ILMN
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director King David P was granted 2,072 shares (SEC Form 4)
- Director Siegel Susan E was granted 2,072 shares, increasing direct ownership by 14% to 16,535 units (SEC Form 4)
- Director Ullem Scott B. was granted 2,072 shares, increasing direct ownership by 24% to 10,863 units (SEC Form 4)
- Director Schiller Philip W was granted 2,072 shares, increasing direct ownership by 10% to 22,220 units (SEC Form 4)
- Director Richo Anna was granted 2,072 shares, increasing direct ownership by 32% to 8,527 units (SEC Form 4)